This Article Full Text Full Text (PDF) Correction (v50,pe56) All Versions of this Article: 50/2/439    most recent HYPERTENSIONAHA.107.090423v2 HYPERTENSIONAHA.107.090423v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, M. S. Articles by Lee, J. Y. Search for Related Content PubMed PubMed Citation Articles by Lee, M. S. Articles by Lee, J. Y. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information High Blood Pressure Related Collections Clinical genetics Cardiovascular Pharmacology Hypertension - basic studies Genetics of cardiovascular disease Receptor pharmacology

(Hypertension. 2007;50:439.)
© 2007 American Heart Association, Inc.

Original Articles

Prevention of Erythropoietin-Associated Hypertension

From the School of Medicine (M.S.L.), Northwestern University, Chicago, Ill; and the Department of Medicine (J.S.L., J.Y.L.), University of Minnesota School of Medicine, Minneapolis.

Hypertension is the most significant complication from treatment with erythropoietin (Epo). Can Epo-induced hypertension be eliminated? We examined systemic and local effects of our genetically engineered products, Epo-binding protein (Epo-bp) and anti–Epo-bp antibodies, on randomly assigned Sprague–Dawley rats at midnight, 4 AM, 8 AM, noon, 4 PM, and 8 PM. Blood pressure, hematocrit, and body weight were measured immediately before and after the completion of a 4-week, twice-weekly course of Epo (50 U/kg), Epo-bp, anti–Epo-bp antibodies, or physiological saline injections. Epo treatment increased hematocrit markedly overall as compared with the saline, Epo-bp, and anti–Epo-bp antibody groups (0.616 versus 0.427, 0.439, and 0.441, respectively) and at each of the 6 test times (all P<0.0001). Epo-bp and anti–Epo-bp antibody treatment with Epo had almost no effect on the Epo-induced hematocrit increase (0.616 versus 0.580 or 0.591, respectively). Circadian blood pressures for Epo versus saline, Epo-bp, and anti–Epo-bp antibody groups were 136.2±2.3 versus 116.2±1.7, 118.4±2.1, and 116.6±2.1 mm Hg, respectively (each P<0.0001). Significantly increased blood pressure was detected at noon, 4 PM, 8 PM, and midnight in Epo treatment. When Epo was given with Epo-bp or anti–Epo-bp antibodies, blood pressure was maintained at similar levels as in saline treatment (each P<0.0001) as compared with Epo treatment alone. Overall, body, brain, and heart weights were significantly lower in Epo treatment than those of other groups. Thus, Epo-bp and anti–Epo-bp antibodies eliminate Epo-induced hypertension without affecting hematocrit and blood volume.

Key Words: erythropoiesis • erythropoietin-binding protein • circadian effects • hypertension • splenomegaly • cardiovascular parameters

This article has been cited by other articles:

				R. Krapf and H. N. Hulter Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA) Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 470 - 480. [Abstract] [Full Text] [PDF]